PSCA and cancer: Additionally, the prostate stem cell antigen (PSCA), overexpressed in a range of malignancies including mCRPC, is the target of GEM3PSCA, an affinity-tailored T cell adaptor that is currently being evaluated in a phase 1 clinical trial (NCT03927573) for PSCA-positive cancer [84].